Table 2.
Subgroup analysis of pooled HRs for OS in cancer patients with abnormal expression level of CXCL5
| Subgroup analysis | No. of cohorts | Pooled HRs | Meta regression (p value) | Heterogeneity | |
|---|---|---|---|---|---|
| Random | I2 (%) | p value | |||
| Sample size | 0.602 | ||||
| < 100 | 8 | 1.60 [0.81–3.17] | – | 70.9 | 0.001 |
| ≥ 100 | 9 | 1.69 [1.37–2.08] | – | 62.0 | 0.007 |
| Type of cancer | 0.197 | ||||
| Digestive system carcinoma | 10 | 1.78 [1.39–2.28] | – | 45.3 | 0.058 |
| Non-digestive system carcinoma | 7 | 1.59 [1.09–2.31] | – | 64.0 | 0.011 |
| Follow-up time | 0.204 | ||||
| < 100 | 10 | 1.75 [1.32–2.32] | – | 69.6 | 0.001 |
| ≥ 100 | 7 | 1.60 [1.07–2.39] | – | 58.6 | 0.024 |
| Samples detected | 0.186 | ||||
| Blood | 3 | 1.90 [1.31–2.76] | – | 0.0 | 0.680 |
| Tissue | 14 | 1.65 [1.28–2.12] | – | 69.8 | 0.000 |
| NOS score | 0.526 | ||||
| ≥ 7 | 12 | 1.71 [1.36–2.15] | – | 49.6 | 0.026 |
| < 7 | 5 | 1.82 [1.10–2.99] | – | 57.2 | 0.053 |
| Source of HR | 0.209 | ||||
| Directly | 10 | 1.61 [1.24–2.09] | – | 72.2 | 0.000 |
| Indirectly | 7 | 1.91 [1.27–2.88] | – | 38.6 | 0.134 |